Le Lézard
Classified in: Science and technology, Business
Subjects: TNM, SHM

VM HOTEL ACQUISITION CORP. ANNOUNCES EXTENSION AND REDEMPTION AMOUNT


TORONTO, Sept. 28, 2023 /CNW/ - VM Hotel Acquisition Corp. (TSX: VMH.U) (TSX: VMH.WT.U) (the "Corporation" or "VMH"), announced today that the resolution put to the holders ("Shareholders") of the Corporation's class A restricted voting shares (the "Class A Restricted Voting Shares") at the special meeting of Shareholders held virtually on September 28, 2023 (the "Meeting"), was approved.

The Corporation announced that the resolution to extend the date by which the Corporation has to consummate a qualifying acquisition from September 30, 2023 to February 29, 2024 (the "Extension"), was approved by the affirmative vote of 98.594% of the votes represented at the Meeting. Following the receipt of approval of the Shareholders, the board of directors approved the Extension, effective as of September 28, 2023.

In connection with the Meeting, VMH provided Shareholders with the opportunity to deposit their Class A Restricted Voting Shares for redemption (the "Redemption"). After calculating the Part Vl.1 taxes under the Income Tax Act (Canada) payable in connection with the Redemption, VMH expects that the amount that each Class A Restricted Voting Share that was deposited for redemption in connection with the Extension will be redeemed for is approximately US$10.21. 3,000 Class A Restricted Voting Shares were deposited for redemption in connection with the Extension. A copy of the complete report on voting at the Meeting will be made available under the Corporation's profile on SEDAR+ at www.sedarplus.ca.

VMH is a special purpose acquisition company incorporated under the laws of the Province of British Columbia for the purpose of effecting a qualifying acquisition within a specified period of time. VMH's head office is located at Brookfield Place, 161 Bay Street, Suite 2420, Toronto, ON, M5J 2S1 and the registered office is located at 1600 - 925 West Georgia Street Vancouver, BC V6C 3L2.

Forward Looking Statements

This press release may contain forward?looking information within the meaning of applicable securities legislation, which reflects the Corporation's current expectations regarding future events. Forward?looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Corporation's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward?looking information. The Corporation does not undertake any obligation to update such forward?looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE VM Hotel Acquisition Corp


These press releases may also interest you

at 04:05
UE Systems, a pioneering force in developing ultrasonic detection instruments and solutions for maintenance and reliability, unveils its latest innovation ? the OnTrak Wireless system. This cutting-edge solution transcends traditional bearing health...

at 04:05
Experian, the global information services company, has today announced the launch of a suite of new capabilities for Ascend, its cloud-based state-of-the-art analytics and technology platform. These latest innovations aim to increase operational...

at 04:00
Pioneering UK-based bio-tech...

at 04:00
Databarracks today announces the launch of Jump-Start, a pre-prepared, cloud-based recovery landing zone. By using Infrastructure as Code (IaC), resources, networking, security, and governance are activated within minutes, ready for a complete...

at 03:59
In Q2 2023, Amador Bioscience, a next generation CRO focusing on translational science and early clinical development, announced the addition of Dr. Lorin Roskos to the Board of Directors. Dr. Roskos has also taken on the roles of Chief Scientific...

at 03:50
--The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subjects --The protocol of Phase III clinical trial has been agreed by Center for Drug Evaluation, National Medical Products Administration and obtained the...



News published on and distributed by: